JJDC and Janssen Immunology invest in BiomX, a pioneering microbiome therapeutics company
The microbiome represents a dramatically new frontier of medicine, with advances occurring in parallel across many modalities and disease areas. Underscoring the vast potential in this field, JJDC co-led an investment with Janssen Immunology and its IBD team in BiomX, Ltd., a pioneering microbiome therapeutics company.
Date or reference or blank 5 June 2017
Collaboration on Hyperdrive: Celebrating One Year of Successes at JLABS @ Toronto
This past year has been arguably the most exciting in history for Toronto’s life science community, with a new energy that’s percolating from the city’s core. There’s no question that Johnson & Johnson Innovation JLABS has been the catalyst for this.
It was just one seemingly short year ago that the first international JLABS location opened its doors right here in the scientific and medical heart of Toronto.
3D Printing: Bringing Emerging Technology to Orthopedics
What began several years ago as a collaboration between Johnson & Johnson Innovation and a pioneering medical device start-up company called Tissue Regeneration Systems (TRS), has evolved into an acquisition that will enable the Johnson & Johnson Family of Companies to advance a truly novel 3D printing technology for bone trauma and deformities.